Canaccord Genuity Initiates Coverage On Vertex Pharmaceuticals with Hold Rating, Announces Price Target of $311
Canaccord Genuity analyst Whitney Ijem initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold rating and announces Price Target of $311.